Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Access Bio
Boyce, Virginia, United Statesaccessbio.net ↗
- Ownership
- Private
- Employees
- ~101
- Development stage
- Other
01
Overview
Access Bio has commercialized multiple rapid and molecular diagnostic products for infectious diseases including malaria, COVID‑19, HIV, and HPV. Its CareStart™ line of COVID‑19 tests received FDA Emergency Use Authorization for both point-of-care antigen/serology kits and laboratory PCR tests. The company’s malaria RDTs are widely used globally. No clinical trial results are reported as the company does not develop therapeutics.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Diagnostic test (in vitro diagnostic)Molecular diagnosticsBiosensor technologyRapid diagnostic test
- Industry
- Molecular Diagnostics
02
Partnerships
Bill & Melinda Gates FoundationWorld Health Organization (WHO)UNICEF
Beyond the preview
Go deeper on Access Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Access Bio.